M3, Inc. (TSE:2413) is another Japanese company that has flourished by helping pharmaceutical companies to more effectively deliver drug information to doctors online. Leveraging its doctor network and technology platform, M3 entered the contract research organization (CRO) space a few years ago and has become one of the top three CRO companies in Japan. The company’s platform automates and optimizes portions of the clinical trial process to help bring drugs to market faster and cheaper.
From Roger Edgley's 1st Quarter 2017 Wasatch International Growh Fund Shareholder Letter.
